综述: 卵巢癌生物标志物的糖链谱研究进展
DOI:
作者:
作者单位:

西北大学生命科学学院功能糖组学实验室,第四军医大学唐都医院妇产科,西北大学生命科学学院功能糖组学实验室

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金资助项目(81372365)


Review: Progress in The Study of Glycosylation of Ovarian Cancer Biomarkers
Author:
Affiliation:

Northwest University,第四军医大学唐都医院妇产科,西安710038,Northwest University

Fund Project:

This work was supported by a grant from The National Natural Science Foundation of China (81372365)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    糖类抗原125(CA125)被认为是卵巢癌诊断的“金标准”,但在临床应用中普遍存在着特异性不高的问题.肿瘤形成和发展过程中常伴有糖基化修饰异常和糖链结构的改变,不同的肿瘤具有特异的异常糖链结构.近年来,借助凝集素芯片、多重质谱分析等糖蛋白组学和糖组学研究技术,发现不同来源CA125的O-糖链和N-糖链结构存在着明显的微观不均一性,以这些特征性糖链结构为标志物,可以显著提高CA125对卵巢癌的诊断特异性.在过去的10年,研究者们除对CA125糖链结构和糖基化模式做了深入的研究外,还利用糖组的研究方法,直接对来自卵巢癌患者血液、体液(腹水、囊泡液等)中糖蛋白的糖链做了精细的结构解析,结果显示,可有效鉴别卵巢癌患者和健康志愿者的特异性N-糖链结构,有可能成为灵敏度高和特异性好的卵巢癌生物标志物.卵巢癌生物标志物研究发展的总趋势是从传统的对蛋白质的定性和定量研究,逐步转向于对标志物糖基化修饰和特异性糖链结构的鉴定以及定量分析.本文从糖组学的视角,对卵巢癌标志物糖组学的研究现状及发展趋势进行了综述和展望.

    Abstract:

    CA125 is a gold standard for the diagnosis of ovarian cancer, however, its specificity is still relatively low in clinical application. Tumor formation and development process is often accompanied by abnormal glycosylation modification and changes in glycan structures. The different tumors have specifically abnormal glycan structures. In recent years, the technologies in glycoproteomics and glycomics, such as lectin microarrays and multiple mass spectrometry, are used to discover the small discrepancies of N- and O-linked glycan structures in CA125 of the different sources. These abnormal glycan structures could increase the specificity of CA125 for the diagnosis of ovarian cancer. In the past decade, the technologies of glycome were also used to directly analyze the subtle glycan structures in the serum and body fluid (ascites, vesicle fluid, etc.) from patients with ovarian cancer. The results showed that the N-linked glycan structures can effectively identify ovarian cancer patients and healthy volunteers, which may be new biomarkers with better sensitivity and specificity for the diagnosis of ovarian cancer. Trends in the development of biomarkers for ovarian cancer shifted from qualitative and quantitative studies of proteins, to identification and quantitative analysis of glycosylation modification and glycan structures of biomarkers. Taking the perspective of glycomics, the status and development trend of ovarian cancer biomarkers are reviewed and discussed in this paper.

    参考文献
    相似文献
    引证文献
引用本文

薛添,李艳红,李铮.综述: 卵巢癌生物标志物的糖链谱研究进展[J].生物化学与生物物理进展,2017,44(10):865-876

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2017-04-10
  • 最后修改日期:2017-05-28
  • 接受日期:2017-09-04
  • 在线发布日期: 2017-10-18
  • 出版日期: 2017-10-20